SOURCE: Equity Markets Inc

September 20, 2011 09:54 ET

Global Situation & Resulting Influences - Research Report on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics

MACAU--(Marketwire - Sep 20, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Nektar Therapeutics (NASDAQ: NKTR). Full content and research is available at www.EquityMarketsInc.com/research.php?id=ACHN+NKTR.

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed Achillion Pharmaceuticals, Inc. for its current position within the healthcare industry. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The full research report on Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is available here: www.EquityMarketsInc.com/research.php?id=ACHN.

Equity Markets has reviewed Nektar Therapeutics for its development within the healthcare industry. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The Company's product pipeline consists of drug candidates across a range of therapeutic areas, including oncology, pain. The full research report on Nektar Therapeutics (NASDAQ: NKTR) is available here: www.EquityMarketsInc.com/research.php?id=NKTR.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information